Intranasal Insulin for Treating Posttraumatic Stress Disorder
VA Connecticut Healthcare System
Summary
To evaluate if intranasal insulin is effective in reducing PTSD symptoms.
Description
The current proposal aims to study the pharmacotherapeutic effects of intranasal insulin on PTSD symptoms and inhibition of amygdala hyperactivation in subjects with PTSD.
Eligibility
- Age range
- 21–65 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male or female, 21-65 years old * Current PTSD * Able to provide written informed consent Exclusion Criteria: * Unstable medical condition, clinically determined by a physician * Diabetes requiring insulin or oral hypoglycemic agents * Moderate-severe traumatic brain injury * Current psychotic disorder, bipolar disorder, cognitive disorder in the past 12 months * Current substance use disorders (except alcohol, tobacco, or cannabis) in the past 3 months * Changes in doses of psychotropic medications in the past 4 weeks * Initiation of individual therapy or counseling i…
Interventions
- DrugIntranasal insulin
Subjects in this arm will receive intranasal insulin (80 IU per day).
- DrugPlacebo
Subjects in this arm will receive placebo.
Location
- VA Connecticut Healthcare SystemWest Haven, Connecticut